Home > News > Company news

Strategic Cooperation Agreement Reached between Tomophase Incorporation and Institute of Computer Application Engineering (Huaruan Group), South China University of Technology

2014-06-30 14:53:32 Tomophase Read

tomophaseGuangzhou, China – June 30, 2014 – Tomophase Incorporation, a leading developer of minimally invasive optical coherence tomography (OCT) tissue imaging devices, announced today that Tomophase Incorporation and the Institute of Computer Application Engineering, South China University of Technology (Huaruan Group), signed the strategic cooperation agreement in Guangzhou, china. The Strategic planning is mainly to promote the software & hardware research for the next generation application for OCT technology. 


About Huaruan Group

Guangzhou Huagong Information Software Co., Ltd. (hereinafter referred to as "Huasoft Group") was founded in October 2001, is a wholly-owned enterprise by the South China University of Technology. The company was overall restructured from the Institute of Computer Application Engineering, South China University of Technology, with a registered capital of RMB 50 million. The group now owns 6 subsidiary companies and two divisions.

Huaruan Group was one of the first national recognized software enterprises, high-tech enterprises in Guangzhou City. It obtained ISO9001 international quality standard certification, National Computer Information Integration System Certification (Grade II), and the National Intelligent Construction Engineering Design and Construction Qualification (Grade II).

About Tomophase

Tomophase is a leader in developing bronchoscopic-based systems for interventional pulmonology. Offering significantly higher resolution than either CT scan or ultrasound, OCTIS provides real-time, high resolution, sub-surface tissue imaging of airways and lungs, to be followed by diagnostic and therapeutic applications. Our goal is to provide physicians with heretofore unobtainable airway microstructural images to improve the management and clinical outcome of pulmonary disease. The company has 15 patent and applications issued and pending. FDA 510(k) clearance for OCTIS was received and the CE Mark is expected in 2015. The U.S. commercial launch is underway and the EU rollout is proceeding. The company is currently raising investment capital to meet the increasing international demand for the OCT Imaging System. Examples of our tissueimaging results are available at